雷公藤多苷联合缬沙坦治疗特发性膜性肾病的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 雷公藤多苷联合缬沙坦治疗特发性膜性肾病的临床观察
TITLE:
摘要:

目的:观察雷公藤多苷联合缬沙坦治疗特发性膜性肾病(IMN)的疗效及安全性。方法:85 例IMN患者,按随机数字表法

分为观察组(42 例)和对照组(43 例),两组患者均给予降脂、抗血小板聚集、限制蛋白饮食等常规治疗。对照组患者在常规治疗基

础上加用缬沙坦80 mg,qd,若未出现明显不良反应,剂量增加至160 mg,qd;观察组患者在对照组基础上加用雷公藤多苷片40

mg,tid,症状完全缓解后减至20 mg,tid。两组患者均治疗12 个月。结果:观察组患者总有效率为92.86%,显著高于对照组的

74.42%,差异有统计学意义(P<0.05);治疗后,两组患者24 h 尿蛋白定量、总胆固醇(TC)、甘油三酯(TG)水平较治疗前下降,观

察组患者血清白蛋白(ALB)水平较治疗前升高,且24 h 尿蛋白定量和TG水平低于对照组,血清ALB水平高于对照组,差异均有

统计学意义(P<0.05 或P<0.01)。两组患者均未见明显不良反应发生。结论:雷公藤多苷联合缬沙坦可有效改善IMN患者的肾

功能和血脂水平,且具有较高的安全性。

ABSTRACT:

OBJECTIVE:To observe therapeutic efficacy and safety of tripterygium glycosides combined with valsartan in the

treatment of idiopathic membranous nephropathy(IMN). METHODS:A total of 85 patients with IMN were enrolled and randomly

divided into observation group(42 cases)and control group(43 cases). Based on routine treatment(reducing lipid,anti-platelet aggregation,

protein dietary restriction),control group was additionally given oral valsartan,with initial dose of 80 mg/d,and gradually

adding the amount to 160 mg/d if there was no obvious ADR;based on control group,observation group was additionally given

Tripterygium glycosides tablet 40 mg,tid,and reducing the amount to 20 mg,tid after complete remission. 2 groups were treated

for 12 months. RESULTS:Total effective rate of observation group was 92.86%,which was significantly higher than that of control

group(74.42%),with statistical significance(P<0.05). Compared with before treatment,the levels of 24 h urine protein,TC

and TG of 2 groups were decreased after treatment,and serum albumin(ALB)of observation group increased;24 h urine protein

and TG of observation group was lower than control group,while the serum level of ALB was higher than control group,with statistical

significance(P<0.05 or P<0.01). No obvious ADR was found in 2 groups. CONCLUSIONS:Tripterygium glycosides combined

with valsartan can improve the kidney function and blood lipid level of IMN patients with high safety.

期刊: 2015年第26卷第35期
作者: 凌俐,魏革,陈丽,谢兆莉
AUTHORS: LING Li,WEI Ge,CHEN Li,XIE Zhao-li
关键字: 雷公藤多苷;缬沙坦;联合用药;特发性膜性肾病;免疫抑制治疗
KEYWORDS: Tripterygium glycosides;Valsartan;Drug combination;Idiopathic membranous nephropathy;Immunosuppressive
阅读数: 223 次
本月下载数: 0 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!